SCHEMBL3315239

SCHEMBL3315239

CC1(NC(=O)OC(C)(C)C)CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.47
CYP2D6 P10635 9/20 0.47
CYP2C9 P11712 7/20 0.47
CYP2C19 P33261 5/20 0.47
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
HIF1A Q16665 3/20 0.42
OPRD1 P41143 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRK1 P41145 1/20 0.42
OPRL1 P41146 1/20 0.42
TSHR P16473 4/20 0.41
CYP1A2 P05177 3/20 0.41
ALDH1A1 P00352 2/20 0.41
USP2 O75604 2/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30713578 0.82 CYP3A4 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL4782320 0.82 CYP3A4 (0.51) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL7391113 0.81 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL30713478 0.79 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL21640024 0.79 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL9359089 0.78 CYP3A4 (0.49) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL30713496 0.78 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL30713657 0.78 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL14684169 0.78 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL30713580 0.77 CYP3A4 (0.39) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115151-B2 Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof ABBVIE INC. (US) 2015-08-25 US disclosed
US-9115151-B2 Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof ABBVIE INC. (US) 2015-08-25 US disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 US disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 US disclosed
WO-2014089904-A1 TRIAZINONE COMPOUNDS ABBVIE INC. (US) 2014-06-19 WO disclosed
WO-2014089904-A1 TRIAZINONE COMPOUNDS ABBVIE INC. (US) 2014-06-19 WO disclosed
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R&D) LIMITED (GB) 2010-04-29 US disclosed
EP-1933830-A1 ANTAGONISTS OF SNS SODIUM CHANNELS Vernalis (R&D) Limited (GB) 2008-06-25 EP disclosed
WO-2007007057-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R & D) LIMITED (GB) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS CNR1, OPRL1, CHRNA10 CYP3A4 1180/4885CYP2D6 797/4885CYP2C9 1041/4885
US-20140206663-A1 TRIAZINONE COMPOUNDS THPO, IL5, CYP11B2 CYP3A4 21/4885CYP2D6 10/4885CYP2C9 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.